Melanoma

>

Latest News

Adjuvant Vaccine Combo May Prolong Survival in Melanoma
Adjuvant Vaccine Combo May Prolong Survival in Melanoma

May 20th 2024

A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.

BLA for Subcutaneous Nivolumab Accepted by the FDA for Advanced/Metastatic Solid Tumors
BLA for Subcutaneous Nivolumab Accepted by the FDA for Advanced/Metastatic Solid Tumors

May 18th 2024

Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma

April 19th 2024

Cancer Vaccine Plus Nivolumab/Ipilimumab Did Not Improve PFS in Metastatic Melanoma
Cancer Vaccine Plus Nivolumab/Ipilimumab Did Not Improve PFS in Metastatic Melanoma

March 8th 2024

Experience, Communication May Help Oncology Nurses Learn More About TIL Therapy in Advanced Melanoma
Experience, Communication May Help Oncology Nurses Learn More About TIL Therapy in Advanced Melanoma

February 22nd 2024

Latest CME Events & Activities

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.